Paige AI vs Abridge

Abridge has a disclosed valuation of $850M, while Paige AI's valuation is not publicly available, making a direct size comparison difficult. Abridge employs 120 people.

Abridge has raised more in total funding at $150M, compared to Paige AI's $125M — a gap of $25M. Combined, the two companies have completed 5 known funding rounds.

Abridge holds the higher Awaira Score at 76/100, compared to Paige AI's 65/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 11-point gap that reflects meaningful differences in scale or traction.

Paige AI was founded by Leo Grady in 2018. Abridge was founded by Shiv Rao in 2018. Visit each company's profile on Awaira for a full founder biography.

Paige AI: Paige AI develops AI-powered pathology software that assists pathologists in identifying cancer and other diseases in digital whole-slide images. The platform received the first-ever FDA authorization for an AI-based primary diagnostic tool in pathology, a milestone that establishes regulatory precedent for clinical AI deployment in histopathology workflows.\n\nThe company raised approximately 125 million USD and partners with major academic medical centers and pathology laboratories to integrate its diagnostic AI into clinical workflows. Paige has expanded beyond prostate cancer detection into additional cancer types and is building a multi-cancer detection platform intended to function as a comprehensive AI layer across pathology departments.\n\nDigital pathology combined with AI represents one of the clearest near-term commercialization opportunities in medical AI, as the transition from glass slides to whole-slide imaging creates a digital substrate that AI can operate on at scale. Paige FDA clearance creates a significant regulatory moat that competitors must match before selling comparable diagnostic tools in the US market, giving the company a durable first-mover advantage in the AI-augmented pathology workflow. Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology leverages natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence.

Both Paige AI and Abridge were founded in the same year — 2018. Despite sharing a founding year, they may have launched at different times within that year, which can matter in fast-moving AI markets.

Paige AI has approximately 100-500 employees, while Abridge has approximately 120. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Paige AI and Abridge are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.